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INTRODUCTION
Acute graft-versus-host disease (GVHD) is a major com-
plication after hematopoietic stem cell transplantation, partic-
ularly in recipients of unrelated and HLA-mismatched grafts
[1,2]. Cutaneous involvement is the most frequent manifesta-
tion of acute GVHD, with severity ranging from mild pruritic
morbilliform erythema to exfoliative erythroderma. Less than
half of patients with acute GVHD achieve durable sustained
responses after treatment with high-dose corticosteroids [3].
Response rates of 11% to 40% have been reported after sec-
ondary therapy, but mortality for nonresponders exceeds 75%
[4,5]. Antithymocyte globulin (ATG), a standard treatment for
steroid-resistant acute GVHD, has induced responses in up to
30% of patients, but mortality rates have been reported as
high as 95% [6,7]. A variety of new immunosuppressive agents
have been explored in phase I/II studies [8-12], and clearly,
new treatment modalities are needed to reduce the morbidity
and mortality associated with both GVHD and its therapy.
Through a variety of mechanisms, including alterations
in cell surface antigens and interference in transmembrane
signaling and intracellular activation, UV irradiation has pro-
found immunogenetic effects that can prevent or inhibit
allorecognition between donor and host cells and tissues
[13]. Photochemotherapy with the use of psoralen plus ultra-
violet A light (PUVA) has been used for many years to treat a
variety of dermatologic diseases, including vitiligo, psoriasis,
lichen planus, atopic dermatitis, eczema, and cutaneous T-cell
lymphoma [14]. The beneﬁcial effects seen with PUVA in
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ABSTRACT
Psoralen plus ultraviolet A irradiation (PUVA) has immunomodulatory effects and is used to treat a variety of
immune-mediated dermatologic diseases. We administered PUVA to 103 patients for treatment of steroid-resistant
acute graft-versus-host disease (GVHD) of the skin. Twenty-nine patients had related donors (12 HLA-mismatched)
and 74 had unrelated donors (23 HLA-mismatched). The median onset of GVHD was day 13 after transplantation,
and the median onset of PUVA treatment was day 46. PUVA was administered as secondary therapy for 86 patients
and tertiary therapy or greater for 17 patients. The median number of treatments was 16, and the mean cumulative
exposure was 41 J/cm2. PUVA was generally well tolerated with 8 patients discontinuing therapy because of toxicity.
At the start of PUVA treatment, 48 patients had rash affecting >50% of their body surface area (BSA), and 91 had
rash involving >25% BSA. Of 65 patients who were evaluated after 6 weeks of PUVA treatment, 11 still had rash
involving >50% BSA, 24 had rash involving >25% BSA, and 24 had no rash. The mean daily dose of prednisone at
the start of PUVA therapy was 1.6 mg/kg compared to 0.7 mg/kg after 6 weeks of therapy. Fifty-nine patients (57%)
did not require additional therapy for skin GVHD after starting PUVA. Ninety-two percent of patients developed
chronic GVHD. Fifty-three patients (51%) remain alive at 129-1883 days after transplantation. These results sug-
gest that PUVA can be an effective therapy for steroid-resistant acute GVHD of the skin.
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these immune-mediated disorders led to preliminary testing
in patients with acute [15,16] or chronic GVHD [17-19].
This report describes our experience with the use of PUVA
to treat steroid-resistant acute GVHD of the skin. The
objectives of this study were (1) to assess the clinical response
to PUVA as a treatment for acute GVHD of the skin, and (2)
to determine whether the addition of PUVA would lessen
the requirement for other immunosuppressive GVHD treat-
ments, particularly corticosteroids.
MATERIALS AND METHODS
Selection of Patients
A retrospective analysis was conducted of treatment
results in 103 consecutive cases of patients in hematologic
remission who received PUVA treatment for steroid-resistant
acute GVHD of the skin within 100 days of allogeneic mar-
row or peripheral blood stem cell transplantation at the
Fred Hutchinson Cancer Research Center between July
1994 and May 2000. Thirty-six patients were treated as part
of an institutional review board–approved phase II clinical
study, and 67 patients subsequently received PUVA as stan-
dard therapy. The treatment plans were identical for both
groups. All patients had either cutaneous GVHD that was
partially responsive to corticosteroids after 10 to 14 days of
therapy or cutaneous GVHD that had recurred after initiat-
ing a steroid taper. Patients with concurrent intestinal or
hepatic acute GVHD were treated with PUVA if involve-
ment of those organs was mild and appeared to be resolving.
Prophylaxis, Diagnosis, and Treatment of GVHD
Most patients received methotrexate plus cyclosporine
(CSP) for GVHD prophylaxis [20,21]. Cutaneous GVHD
was diagnosed based on the presence of a characteristic rash,
with or without a conﬁrmatory biopsy. For most patients, a
14-day course of corticosteroids (2 mg/kg per day) was the
initial treatment for acute GVHD. Secondary therapy, other
than PUVA, included ATG, thymoglobulin, mycophenolate
mofetil (MMF), rapamycin, or investigational antibodies.
Continuation of concurrent immunosuppression, initiation
of additional therapy, and tapering of steroids after the start
of PUVA therapy was based on clinical response and was at
the discretion of the attending physician.
PUVA Therapy
PUVA was administered in a full body supine unit (Son-
nenBräune Wolff System 624; SonnenBräune, Ringgold, GA)
equipped with 24 fluorescent bulbs (Nuvalarium N2-10-
100W; Voltarc Technologies, Waterbury, CT). Methoxsalen
(Oxsoralen-Ultra) or 8-methoxypsoralen (8-MOP) was taken
orally at doses of 0.4-0.9 mg/kg, 1.5 to 2 hours before expo-
sure to UVA. Patients were instructed to use appropriate
eye protection for 24 hours after ingesting methoxsalen.
UVA-blocking goggles were worn by all patients during the
treatment, and zinc oxide was applied to the lips. Male
patients had the genital area shielded during therapy. The
starting dose of UVA was 0.25 to 1.0 J/cm2 and, in the
absence of toxicity, exposure was increased in increments of
0.25 J/cm2 per treatment. Patients were initially treated
3 times per week (M/W/F). The frequency of treatment was
later decreased to twice a week if patients showed responses.
Depending on response and patient tolerance, PUVA therapy
was continued for the duration of glucocorticoid treatment or
until patients were discharged from our care.
Measurements of Responses to PUVA Therapy
Responses to PUVA therapy were measured in 3 ways:
(1) the change in skin morbidity deﬁned as the total body
surface area involved with rash, (2) the change in the dose of
steroids during PUVA therapy, and (3) the requirement for
additional therapy for GVHD, including additional steroids.
Skin morbidity was staged as the percentage of body surface
area involved with rash or erythema or the presence of bul-
lae: stage 1, ≤25% of skin surface area involved; stage 2, 26%
to 50%; stage 3, >50%; stage 4, bullae formation. Skin mor-
bidity was staged without consideration for other concomi-
tant factors that might contribute to changes in the skin,
including phototoxicity from PUVA [22]. Steroid doses
were calculated as the total daily dose of oral prednisone
based on body weight (mg/kg per day). Where applicable, a
factor of 1.25 was used to convert intravenous methylpred-
nisolone to the equivalent of prednisone.
Skin morbidity staging and steroid doses were deter-
mined at the start of PUVA therapy and at weekly intervals
for 6 weeks after the start of therapy or until PUVA was dis-
continued, whichever occurred first. Responses to PUVA
therapy were also evaluated according to the reason for dis-
continuing PUVA and the requirement for additional
immunosuppression to treat GVHD after initiating PUVA
therapy. Patient charts were reviewed to determine the need
for additional immunosuppressive therapy for GVHD
through 100 days after transplantation, until recurrence of
malignancy or death, or until discharge to home, whichever
occurred first. In most cases, patients returned home
between 80 and 100 days after transplantation.
PUVA Toxicity
Phototoxicity was assessed by physical exam at each
treatment and was deﬁned as the presence of erythema, ery-
throderma, or tenderness in the skin not caused by GVHD,
as assessed by characteristic sparing of the axillae and other
less exposed surfaces. Toxicity from psoralen was deﬁned as
an elevation in liver function test results or the presence of
nausea/vomiting presumed to be caused by psoralen.
Statistical Analysis
Descriptive statistics were used to summarize changes in
steroid doses during PUVA therapy and the requirement for
additional GVHD therapy after the start of PUVA. Average
daily prednisone doses were calculated for each patient by
week and summarized over time with mean values and stan-
dard errors. Differences between skin morbidity scores
before PUVA therapy and after 6 weeks of treatment, or at
the end of PUVA therapy if treatment was discontinued ear-
lier, were summarized and compared using the Wilcoxon
matched pairs signed rank test.
RESULTS
Patient and GVHD Characteristics
Patient and GVHD characteristics are summarized in
Tables 1 and 2. Twenty-nine patients received marrow or
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peripheral blood stem cells from related donors (17 HLA-
matched, 12 HLA-mismatched), and 74 received transplants
from unrelated donors (51 HLA-matched, 23 HLA-mis-
matched). The median onset of acute GVHD was 13 days
after transplantation. Eighty percent of the patients had
histological confirmation of skin GVHD at some time
before starting therapy or within 5 days after starting
PUVA; 15% did not have a biopsy performed before start-
ing PUVA therapy, and 5% had an equivocal or negative
biopsy for GVHD before starting PUVA therapy. In this
latter group, with one exception, the biopsy was performed
early after transplantation, at the onset of hyperacute
GVHD, when it is very difficult to distinguish GVHD
from chemoradiation damage. Initial treatment for acute
GVHD consisted of corticosteroids alone in 88 patients
(85%). Fifteen patients received other immunosuppressive
therapies for initial treatment, including oral beclometha-
sone, CSP, tresperimus (a deoxyspergualin-like compound),
or an anti-CD3 antibody. Before starting PUVA therapy,
11 patients (11%) had received secondary immunosuppres-
sive therapy for GVHD, and 6 patients (6%) had received
tertiary therapy. At the start of PUVA therapy, 67 patients
(65%) had recurrent GVHD during the first attempt to
taper steroid therapy, and 5 patients (5%) had recurrent
GVHD during each of 2 successive attempts to taper
steroid therapy. Thirty-one patients (30%) had active skin
GVHD after initial therapy and had not yet commenced a
steroid taper before starting PUVA therapy. In evaluating
response to PUVA and tolerance to therapy (phototoxicity),
there appeared to be no difference between those patients
who had previously failed a steroid taper and those who had
not yet commenced a taper.
PUVA Therapy and Skin Response
The median time of initiation of PUVA therapy was
46 days after transplantation. The median number of treat-
ments administered was 16 (range, 1-78), with a mean
cumulative UVA exposure of 41 J/cm2. The median maxi-
mum UVA exposure was 2.5 J/cm2 per treatment. The Fig-
ure shows the change in skin morbidity staging during
6 weeks of therapy. At the start of PUVA therapy (week 0),
12 patients had stage 1 skin morbidity, 43 patients had stage
2, and 48 had stage 3. No patients had stage 4 skin morbid-
ity at the start of therapy. Thirty-eight patients (37%) dis-
continued PUVA therapy before week 6. Thirteen patients
(13%) had PUVA discontinued because of GVHD, 10 because
of progressive skin disease, and 3 because of new-onset intesti-
nal GVHD requiring additional systemic therapy (Table 3).
Of 65 patients who were evaluated after 6 weeks of PUVA
treatment, 24 patients had no rash, 17 had stage 1 skin mor-
bidity, 13 had stage 2, and 11 had stage 3.
Skin morbidity scores decreased significantly for all
patients as seen by scores before the start of PUVA therapy
compared to those after 6 weeks of therapy or, for those
patients in whom treatment was discontinued earlier, at the
end of PUVA therapy (P < .001). Results were also analyzed
based on the duration of therapy. Morbidity scores
decreased signiﬁcantly for patients who completed 6 weeks
of therapy and also for those who discontinued PUVA
before 6 weeks, although the magnitude of the changes for
the latter group was smaller (Table 4).
Requirement of Additional GVHD Therapy
Fifty-one patients (50%) required additional GVHD
therapy after starting PUVA therapy, including increased
doses of steroids (Table 5). Other modalities used to treat
GVHD included tacrolimus, MMF, ATG, thalidomide,
azithioprine, oral beclomethasone, and sirolimus. Forty-four
patients (43%) required additional therapy for GVHD
involving the skin alone or the skin plus other organs, and
7 (7%) required therapy for GVHD limited to the gut
(Table 5). The median time for starting additional immuno-
suppressive therapy was 68 days after transplantation. In
total, 59 patients (57%) did not require additional therapy
for GVHD of the skin after starting PUVA therapy.
Nine patients received 4 or fewer PUVA treatments
before discontinuing therapy. Six of the 9 had progressive
skin GVHD requiring additional systemic therapy. One
patient developed chronic GVHD, 1 patient was discharged
to home in hematologic relapse, and 1 patient refused addi-
tional PUVA therapy because of the risk of phototoxicity.
Table 1. Patient Characteristics (n = 103)
Age, y, median (range) 28 (1-56)
Sex, n
Male 68
Female 35
Disease risk, n*
Low 49
High 54
GVHD prophylaxis, n
Methotrexate/cyclosporine 82
Methotrexate/tacrolimus 4
Other regimens 17
HLA match, n
Related donor
HLA matched 17
HLA mismatched 12
Unrelated donor
HLA matched 51
HLA mismatched 23
*Low-risk diseases included CML in chronic phase; acute leukemia
in first remission; refractory anemia without excess blasts; and lym-
phoma in ﬁrst remission, ﬁrst untreated relapse or second remission.
All other diseases were included in the high-risk category.
Table 2. Characteristics of Acute GVHD (n = 103)
Days between transplantation and onset of GVHD, 13 (4-50)
median (range)
Days between onset of GVHD and treatment with
PUVA, median (range) 30 (11-79)
GVHD treatment regimens before PUVA, n (%)
1 86 (83%)
2 11 (11%)
≥3 6 (6%)
Skin morbidity grade at the start of PUVA, n (%)
Stage 1 12 (12%)
Stage 2 43 (42%)
Stage 3 48 (46%)
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Steroid Dosing
PUVA therapy appeared to have a steroid-sparing effect.
The mean dosage of prednisone at the start of PUVA ther-
apy was 1.6 mg/kg per day. At week 6 of PUVA therapy, the
mean prednisone dosage was 0.7 mg/kg per day (Figure).
Toxicity, Chronic GVHD, and Outcome
Phototoxicity, manifested as mild erythema or tender-
ness in the skin and thought to be related to UVA, devel-
oped in 45 patients (44%). Thirty-ﬁve patients (34%) had
treatment temporarily withheld or required a decrease in
UVA exposure time, and 5 patients (5%) had PUVA therapy
discontinued after 10 to 32 treatments because of phototoxi-
city. Ten patients (10%) developed nausea and vomiting
attributed to psoralen, and therapy had to be discontinued
in 1 patient. One patient had increasing liver function
abnormalities after starting psoralen, and PUVA therapy was
discontinued. One patient with a history of squamous cell
carcinoma had recurrence of the malignancy after 10 PUVA
treatments, and therapy was discontinued.
Eighty-seven (92%) of 95 evaluable patients developed
extensive chronic GVHD. Fifty-three patients (51%)
remain alive 129 to 1883 days after transplantation. The
Kaplan-Meier estimate of survival at 5 years after the start
of PUVA therapy was 43% (data not shown).
DISCUSSION
Our review of PUVA therapy for steroid-resistant acute
skin GVHD suggests that this treatment can be safe and
effective. Analysis of responses to PUVA over 6 weeks of
treatment showed a decline in skin morbidity scores,
thereby allowing a decrease in steroid treatment. Fifty-seven
percent of patients required no additional therapy for skin
Skin morbidity staging and steroid dosing after start of PUVA. Evaluation of skin morbidity and determination of steroid dose began with the start
of PUVA (week 0) and continued at weekly intervals through 6 weeks of therapy or until PUVA was discontinued, whichever occurred ﬁrst (A).
Each week, dosing was captured as the average daily dose of oral prednisone per subject. Mean values ± one standard error are presented. B, Skin
morbidity was categorized as stage 0: , 1: , 2: , or 3: , based on criteria described in methods. The number noted in each grid indicated the
number of patients with designated skin score at the speciﬁed time point. At study weeks 1, 2, and 3, 1 patient had a skin morbidity stage of 4. The
empty bar () indicates the number of patients withdrawn from PUVA therapy. At study week 1, 1 patient had withdrawn from therapy.
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GVHD after starting PUVA. The lack of a control group
and the selection of patients with cutaneous GVHD as their
major problem at the start of therapy limited our ability to
compare results with those of other GVHD treatments. In
some studies of initial or secondary treatment, acute GVHD
of the skin was more responsive than GVHD of the liver or
gastrointestinal tract [4,6,10], but not all studies have sup-
ported this conclusion [5,11]. Also, longitudinal analysis of
skin morbidity scores is biased toward responding patients
who are able to continue therapy. In our study, only 63% of
patients continued to receive PUVA therapy for 6 weeks.
That said, our analysis showed that there was a signiﬁcant
decrease in skin morbidity from the start of PUVA therapy
to the end of treatment, regardless of duration of therapy.
The photobiological effect of PUVA and the mecha-
nisms involved in the generation of immunosuppression to
treat GVHD are not fully understood. In vitro and in vivo,
UVA and UVB irradiation have been shown to deplete cell
surface markers and reduce the number of dendritic epider-
mal cells, speciﬁcally Langerhans cells (LCs), and interfere
with their antigen-presenting capacity [23-26]. Both contact
and delayed hypersensitivity reactions are suppressed fol-
lowing photochemotherapy [27,28]. In controlled studies
with psoriatic patients, the total numbers of CD3+ and
CD4+ peripheral T-cells, as well as the percentage of CD3+
lymphocytes producing interferon-γ (IFN-γ) and inter-
leukin-2 (IL-2), were signiﬁcantly reduced following PUVA
therapy [29-31]. Ultraviolet irradiation also modifies pro-
inflammatory and inhibitory cytokine production in the
epidermis and peripheral mononuclear cells. UV-induced
IL-10 secretion from keratinocytes contributes to systemic
impairment of splenic and LC antigen–presenting function.
Also, the activity of T-helper 1 cells is suppressed by IL-10,
and the production of IL-2 and INF-γ is decreased [32,33].
Studies in healthy individuals and in patients with psoriasis
have demonstrated that PUVA, both in vivo and in vitro,
reduced levels of proinﬂammatory cytokines IL-1, IL-6, IL-8,
and tumor necrosis factor α [34]. The therapeutic benefit
derived from PUVA to treat GVHD is likely because of a
combination of these effects.
The previously reported experience with the use of
PUVA for treatment of acute GVHD consists of case stud-
ies or small series of patients. PUVA therapy has been used
primarily to treat patients with cutaneous GVHD. Our ini-
tial experience in 18 patients using PUVA after failure of
primary or secondary therapy for acute GVHD showed a
response rate of 72% for skin manifestations. Five patients
also showed some improvement of hepatic and enteric
GVHD. Eight of 9 patients with complete response toler-
ated a taper of corticosteroids. Wiesmann et al. reported
an overall response rate of 75% in 20 patients receiving
PUVA as secondary treatment for acute GVHD. In
patients with GVHD limited to the skin, the response rate
was 92%, but only 2 of 6 patients with extracutaneous
involvement had improvement after treatment with PUVA.
Fifty-five percent of patients were alive at the time of the
report [16].
Our experience with PUVA for treatment of acute
GVHD cannot be easily compared to results reported by
other investigators. First, interpretations are limited by dif-
ferences in GVHD risk factors and organ involvement.
Second, most studies have used traditional grading meas-
ures to assess response in skin GVHD [35]. Application of
this grading system is particularly difficult for studies of
PUVA because the treatment can cause cutaneous changes
that are nearly indistinguishable from GVHD. Erythema or
burns secondary to PUVA therapy can occur in 10% to
20% of patients [36,37]. In our series, 44% of patients
developed phototoxicity, with erythema, hyperpigmenta-
tion, or tenderness attributed in part to PUVA. Although a
longitudinal assessment of morbidity involving the skin
does not strictly measure changes in skin GVHD, this
approach may provide a more objective and comprehensive
Table 3. Details of PUVA Therapy
Days between transplantation and treatment 46 (21-95) 
with PUVA, median (range)
Number of treatments, median (range) 16 (1-78)
Cumulative UVA exposure, J/cm2, mean (range) 41 (0.25-696)
Patients discontinuing PUVA before 6 wk, n (%) 38 (37%)
Reasons for discontinuing PUVA
Discharge home 9 (24%)
Progressive skin GVHD 10 (26%)
Other GVHD (not skin) 3 (8%)
Recurrent malignancy 3 (8%)
Toxicity 4 (10%)
Patient refusal 3 (8%)
Other* 6 (16%)
*Treatment for chronic GVHD (n = 2), too ill to continue therapy
(n = 2), resolution of rash (n = 1), prednisone dose increased for treat-
ment of idiopathic pneumonitis syndrome (n = 1).
Table 4. Change in Skin Morbidity Score during PUVA Therapy
Duration of No. of Change in Score,
PUVA Therapy Patients Mean (SD) P*
6 wk 65 –1.15 (1.18) <.001
<6 wk 38 –0.42 (0.95) .02
*P value from Wilcoxon signed rank test comparing pre-PUVA to
ﬁnal score.
Table 5. Outcome after PUVA Treatment (n = 103)
Patients requiring additional therapy for GVHD 51 (50%)
after starting PUVA treatment, n (%)
Treatment modalities, n
Increased corticosteroids 41
Mycophenoalte mofetil 16
Tacrolimus 7
Antithymocyte globulin 6
Other 16
Affected organs requiring additional treatment 
for GVHD, n
Skin alone 23
Skin plus other organ(s) 21
Other organ (excluding skin) 7
Extensive chronic GVHD, n (%)
Yes 87 (92%)
No 8 (8%)
Not evaluable 8
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assessment of outcome for the skin. Third, we have evalu-
ated results with respect to concomitant steroid treatment
and the need for additional immunosuppressive therapy,
outcomes that are sometimes not included in published
reports. In our study the use of PUVA appeared to have a
steroid-sparing effect. To further assess the benefits of
PUVA, a prospective randomized controlled study is
needed. Consideration should be given to testing this ther-
apy in combination with steroids versus steroids alone as
primary treatment for acute GVHD of the skin.
PUVA therapy appeared to be well tolerated. Although
44% of patients experienced some degree of phototoxicity,
only 5% had therapy discontinued because of phototoxicity.
To date, only 1 patient in this series has developed a cuta-
neous malignancy, and this patient had a history of squamous
cell carcinoma before transplantation. Continued surveil-
lance of patients, however, will be needed to determine the
long-term risk of skin cancers after the use of PUVA for
treatment of GVHD.
Our results suggest that PUVA can serve as a safe and
effective treatment for acute GVHD involving the skin.
Although it is difficult to compare the efficacy of this
approach to other GVHD treatments, PUVA appears to
have a steroid-sparing effect and may alleviate the need to
use the other systemic immunosuppression that may have
increased toxicity.
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